Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

NCT00060476 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

15000

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: rofecoxib
DRUG: Comparator: placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC